Jpmorgan Chase & CO Cara Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CARA
# of Institutions
84Shares Held
16.4MCall Options Held
55KPut Options Held
500-
Vanguard Group Inc Valley Forge, PA2.25MShares$652,5960.0% of portfolio
-
Disciplined Growth Investors Inc Minneapolis, MN1.94MShares$561,3580.01% of portfolio
-
Chescapmanager LLC Baltimore, MD1.7MShares$493,6110.04% of portfolio
-
Farallon Capital Management LLC San Francisco, CA1.56MShares$451,3120.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.07MShares$309,0670.0% of portfolio
About Cara Therapeutics, Inc.
- Ticker CARA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,725,900
- Market Cap $15.6M
- Description
- Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...